A Supplement on Cognitive Function and Brain Activity in Middle Age and Older Healthy Adults
NCT05892627, Early phase 1, Unknown, Aberystwyth University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Supplement on Cognitive Function and Brain Activity in Middle Age and Older Healthy Adults | ClinicalTrials.gov |
| NCT number | NCT05892627 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Early phase 1 | ClinicalTrials.gov |
| Enrollment | 40 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Aberystwyth University | ClinicalTrials.gov |
| Conditions | Cognitive Decline | ClinicalTrials.gov |
| Interventions | PoZibio, Placebo | ClinicalTrials.gov |
| First posted | 2023-06-07 | ClinicalTrials.gov |
| Last updated | 2023-06-07 | ClinicalTrials.gov |
Registered outcomes 22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Cognitive Control (Selective attention, processing speed, mental flexibility) | Improved score (faster response time and improved accuracy) from baseline score at 6 weeks after pozibio | Cognitive Control (Selective attention, processing speed, mental flexibility) measured using the Stroop task in E-Prime | ClinicalTrials.gov |
| Primary | Cognitive Control (Selective attention, processing speed, mental flexibility) | Improved score (faster response time and improved accuracy) at 6 weeks after pozibio when compared with placebo after 6 weeks | Cognitive Control (Selective attention, processing speed, mental flexibility) measured using the Stroop task in E-Prime | ClinicalTrials.gov |
| Primary | Response inhibition (core construct in cognitive control and self-regulation) | Improved (fewer commission errors) score from baseline score at 6 weeks after pozibio | Measured using the Go/No-go task in E-Prime | ClinicalTrials.gov |
| Primary | Response inhibition (core construct in cognitive control and self-regulation) | Improved (fewer commission errors ) score at 6 weeks after pozibio when compared with placebo after 6 weeks | Response inhibition (core construct in cognitive control and self-regulation) measured using the Go/No-go task in E-Prime | ClinicalTrials.gov |
| Primary | Selective attention and response inhibition (core constructs in cognitive control and self-regulation) | Improved score (faster response time and improved accuracy) from baseline score at 6 weeks after pozibio | Selective attention and response inhibition (core constructs in cognitive control and self-regulation) measured using the Flanker task in E-Prime | ClinicalTrials.gov |
| Primary | Selective attention and response inhibition (core constructs in cognitive control and self-regulation) | Improved score (faster response time and improved accuracy) at 6 weeks after pozibio when compared with placebo after 6 weeks | Selective attention and response inhibition (core constructs in cognitive control and self-regulation) measured using the Flanker task in E-Prime | ClinicalTrials.gov |
| Primary | Electroencephalogram (EEG) during the Stroop task | After 6 weeks of pozibio, no delay of the P3 component and more N2 components when compared with baseline | Assessing event related potentials (ERP's) in the P3 component and the N2 component across the frontal and parietal regions | ClinicalTrials.gov |
| Primary | Electroencephalogram (EEG) during the Stroop task | After 6 weeks of pozibio, no delay of the P3 component and more N2 components when compared with 6 weeks of placebo | Assessing event related potentials (ERP's) in the P3 component and the N2 component across the frontal and parietal regions | ClinicalTrials.gov |
| Primary | Electroencephalogram (EEG) during the Flanker task | After 6 weeks of pozibio, no delay of the P3 component and more N2 components when compared with baseline | Assessing event related potentials (ERP's) in the P3 component and the N2 component across the frontal and parietal regions | ClinicalTrials.gov |
| Primary | Electroencephalogram (EEG) during the Flanker task | After 6 weeks of pozibio, no delay of the P3 component and more N2 components when compared with 6 weeks of placebo | Assessing event related potentials (ERP's) in the P3 component and the N2 component across the frontal and parietal regions | ClinicalTrials.gov |
| Primary | Electroencephalogram (EEG) during the go/no-go task | After 6 weeks of pozibio, no delay of the P3 component and more N2 components when compared with baseline | Assessing event related potentials (ERP's) in the P3 component and the N2 component across the frontal and parietal regions | ClinicalTrials.gov |
| Primary | Electroencephalogram (EEG) during the go/no-go task | After 6 weeks of pozibio, no delay of the P3 component and more N2 components when compared with 6 weeks of placebo | Assessing event related potentials (ERP's) in the P3 component and the N2 component across the frontal and parietal regions | ClinicalTrials.gov |
| Primary | Electroencephalogram (EEG) during the stroop task | After 6 weeks of pozibio, increased alpha and delta activity when compared with baseline | Assessing alpha and delta activity | ClinicalTrials.gov |
| Primary | Electroencephalogram (EEG) during the Flanker task | After 6 weeks of pozibio, increased alpha and delta activity when compared with baseline | Assessing alpha and delta activity | ClinicalTrials.gov |
| Primary | Electroencephalogram (EEG) during the go/no-go task | After 6 weeks of pozibio, increased alpha and delta activity when compared with baseline | Assessing alpha and delta activity | ClinicalTrials.gov |
| Primary | Electroencephalogram (EEG) during the stroop task | After 6 weeks of pozibio, increased alpha and delta activity when compared with 6 weeks of placebo | Assessing alpha and delta activity | ClinicalTrials.gov |
| Primary | Electroencephalogram (EEG) during the Flanker task | After 6 weeks of pozibio, increased alpha and delta activity when compared with 6 weeks of placebo | Assessing alpha and delta activity | ClinicalTrials.gov |
| Primary | Electroencephalogram (EEG) during the go/no-go task | After 6 weeks of pozibio, increased alpha and delta activity when compared with 6 weeks of placebo | Assessing alpha and delta activity | ClinicalTrials.gov |
| Primary | EuroQol 5 Dimension 5L (combined score) | Reduced score from baseline EuroQol 5 Dimension 5 score at 6 weeks after pozibio | EuroQol 5 Dimension 5 5L questionnaire: Generic quality of life. Mobility- Level 1-5 Self-Care- Level 1-5, Usual Activities- Level 1-5, Pain/Discomfort- Level 1-5, Anxiety/Depression- Level 1-5. The digits for the five dimensions will be combined into a 5-digit number that describes the patient's health state. | ClinicalTrials.gov |
| Primary | EuroQol 5 Dimension 5L (combined score) | Reduced EuroQol 5 Dimension 5 score at 6 weeks after pozibio when compared with placebo after 6 weeks | EuroQol 5 Dimension 5 5L questionnaire: Generic quality of life. Mobility- Level 1-5 Self-Care- Level 1-5, Usual Activities- Level 1-5, Pain/Discomfort- Level 1-5, Anxiety/Depression- Level 1-5. The digits for the five dimensions will be combined into a 5-digit number that describes the patient's health state. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Eriksen Flanker Task | Primary outcome | ConductCognition |
| Go/No-Go Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)